Stock Events

Stock Events

United Therapeutics 

€506.40
165
-€14.80-2.84%Friday 16:30

Statistics

Day High
501.4
Day Low
500.8
52W High
553.2
52W Low
485.3
Volume
-
Avg. Volume
-
Mkt Cap
21.72B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 4Expected
Q2 2026
Q3 2026
5.08
5.49
5.89
6.29
Expected EPS
5.3466954286399995
Actual EPS
5.0823567999999995

Financials

41.91%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
2.77BRevenue
1.16BNet Income

Analyst Ratings

$484.97Average Price Target
The highest estimate is ⁦582.76⁩.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
63%
Hold
25%
Sell
13%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow UTH.XETRA. It's not an investment recommendation.
Microsoft
45
MSFT
Amazon
43
AMZN
NVIDIA
42
NVDA
Meta Platforms
41
META

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline competes in the pulmonary arterial hypertension (PAH) space, a key area for United Therapeutics.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its subsidiary Actelion, offers products that directly compete in the PAH market.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has therapies for cardiovascular diseases, including PAH, making it a competitor.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol Myers Squibb competes in various therapeutic areas with United Therapeutics, including cardiovascular diseases.
Novartis
NVS
Mkt Cap303.67B
Novartis provides treatments for PAH, directly competing with United Therapeutics' portfolio.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie, through its broad range of pharmaceutical products, competes in areas that overlap with United Therapeutics' interests.
Merck
MRK
Mkt Cap368.89B
Merck & Co. has a diverse pharmaceutical portfolio that includes treatments for conditions in competitive areas with United Therapeutics.
Lilly(Eli) &
LLY
Mkt Cap1.26T
Eli Lilly competes in the broader pharmaceutical market, including treatments for conditions that overlap with United Therapeutics' focus areas.
AMGEN
AMGN
Mkt Cap251.94B
Amgen's portfolio includes therapies for cardiovascular diseases, making it a competitor in some of United Therapeutics' markets.
Biogen
BIIB
Mkt Cap37.49B
Biogen, while primarily focused on neurological disorders, has ventured into areas that could compete with United Therapeutics' treatments.

About

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Show More
CEO
Martine A. Rothblatt
Employees
1400
Country
United States
ISIN
US91307C1027
WKN
000923818

Listings

STU
DE
UTH.STU
MU
DE
UTH.MU
XNAS
US
UTHR
F
DE
UTH.F

0 Comments

Share your thoughts

FAQs

What is United Therapeutics stock price today?▼
The current price of UTH.XETRA is €506.40 EUR — it has decreased by -2.84% in the past 24 hours. Watch United Therapeutics stock price performance more closely on the chart.
What is United Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange United Therapeutics stocks are traded under the ticker UTH.XETRA.
What is United Therapeutics market cap?▼
Today United Therapeutics has the market capitalization of 21.72B
When is the next United Therapeutics earnings date?▼
United Therapeutics is going to release the next earnings report on February 24, 2027.
What were United Therapeutics earnings last quarter?▼
UTH.XETRA earnings for the last quarter are 5.08 EUR per share, whereas the estimation was 5.35 EUR resulting in a -4.94% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is United Therapeutics revenue for the last year?▼
United Therapeutics revenue for the last year amounts to 2.77B EUR.
What is United Therapeutics net income for the last year?▼
UTH.XETRA net income for the last year is 1.16B EUR.
How many employees does United Therapeutics have?▼
As of November 8, 2026, the company has 1,400 employees.
In which sector is United Therapeutics located?▼
United Therapeutics operates in the Health & Wellness sector.
When did United Therapeutics complete a stock split?▼
The last stock split for United Therapeutics was on September 23, 2009 with a ratio of 2:1.
Where is United Therapeutics headquartered?▼
United Therapeutics is headquartered in SILVER SPRING, United States.